Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Israel

European Research Council grant · Running

PRIME-ADC Peptide-based Robust and Innovative Molecular Condensate Engineering for Antibody-Drug Conjugates

Coordinator
Tel Aviv University, Israel
Runs
1 October 2026 to 31 March 2028
Status
Running
EU funding
€150k
Total cost
—
Partners
2 organisations in 2 countries
Type
European Research Council grant
Grant agreement
101287796

What the project is doing

In the project's own words, from its summary on CORDIS.

Antibody drug conjugates are among the most promising targeted cancer therapies, combining the specificity of monoclonal antibodies with the potency of cytotoxic drugs. Yet, more than 80% of ADC candidates fail to progress beyond early clinical stages. A key reason lies in current conjugation chemistries: lysine- and cysteine-based methods yield heterogeneous products with unstable linkages, poor pharmacokinetics, and high manufacturing inefficiencies, wasting up to 50% of material.

Copper-catalyzed click chemistry (CuAAC) offers the promise of precise, site-specific conjugation, but copper toxicity has prevented its industrial use, while copper-free alternatives require costly antibody engineering and compromise reaction kinetics. PRIME-ADC introduces a breakthrough solution: peptide-based biomolecular condensates engineered as programmable microreactors for CuAAC conjugation. These condensates selectively recruit antibodies and hydrophobic drugs into their dense phase, enabling efficient, stoichiometric coupling with controlled drug-to-antibody ratios.

At the same time, copper ions remain in the dilute phase and are removed via simple centrifugation, eliminating toxicity risks and simplifying downstream purification. This one-pot, aqueous, and recyclable system yields homogeneous, stable ADCs with predictable pharmacokinetics, while reducing solvent use, energy demand, and purification costs. The proof of concept will validate PRIME-ADC with cetuximab and clinically relevant payloads, benchmark performance against standard chemistries, and demonstrate regulatory-compliant copper clearance.

In parallel, business feasibility will be established through market validation, competitive benchmarking, and the design of a spin-out company. If successful, PRIME-ADC will unlock the clinical and commercial potential of next-generation ADCs, reduce environmental burden, and lay the foundation for a high-growth European biotech venture.

Topics

Who is involved

OrganisationCityCountryRole
Tel Aviv UniversityTel AvivIsraelCoordinator
Day One Societa a Responsabilita LimitataRoma RmItalyParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI